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Abstract Tirasemtiv is a fast skeletal troponin activator that
sensitizes the sarcomere to calcium and increases muscle force
following subtetanic nerve input. In an animal model of my-
asthenia gravis (MG), single oral doses of tirasemtiv improved
muscle force and reduced fatigability. The purpose of this
study was to determine the effect of single doses of tirasemtiv
on skeletal muscle function and fatigability in patients with
generalized MG. Thirty-two patients with acetylcholine
receptor-antibody positiveMG and muscle weakness received
single doses of tirasemtiv (250 mg or 500 mg) or placebo in a
double-blind, randomized treatment sequence with each treat-
ment separated by at least 1 week. Outcome measures includ-
ed the Quantitative MG Score (QMG), MG Composite, Man-
ual Muscle Testing, and forced vital capacity. At 6 h after
dosing, tirasemtiv produced dose-related improvements from
baseline in the QMG score (slope: –0.49 QMG point per
250 mg; p=0.02) and in percent predicted forced vital capac-
ity (slope: 2.2 % per 250 mg; p=0.04). QMG improved
>3 points in twice as many patients after 500 mg
tirasemtiv than after placebo. Both doses of tirasemtiv
were well tolerated; there were no premature termina-
tions or serious adverse events. The results of this study
suggest that tirasemtiv may improve muscle function in
MG and will be used to support further development of
tirasemtiv in neuromuscular diseases.
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Introduction
In myasthenia gravis (MG), weakness and fatigue result
from failure of signal transmission at the neuromuscular
junction due to antibody binding of the acetylcholine
receptor resulting in limited force production [1]. Treat-
ment consists of acetylcholinesterase inhibitors and im-
munosuppression, although weakness and fatigue are still
common in these patients [2].
Tirasemtiv (formerly CK-2017357) is an investigation-
al drug that is a highly selective activator of the fast skel-
etal muscle troponin complex. It was developed as a
means to increase muscle strength by amplifying the re-
sponse of muscle when neuromuscular input is diminished
in diseases such as MG that result in a decrease in muscle
fiber action potentials and, consequently, a decrease in the
number of muscle fibers contracting, thus leading to a
decrease in muscle force production [3]. Tirasemtiv
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selectively activates the fast skeletal muscle troponin
complex by increasing its sensitivity to calcium, thereby
increasing skeletal muscle force in response to neuronal
input and delaying the onset and reducing the degree of
muscle fatigue [3]. Tirasemtiv slows the rate of calcium
release from fast skeletal troponin, thus increasing its af-
finity for calcium and sensitizing muscle to calcium. As a
consequence, the force–calcium relationship of fast skele-
tal muscle fibers shifts leftward and muscle force in-
creases relative to control at submaximal activation. In
preclinical models of nerve–muscle function and in
humans, tirasemtiv amplified the response of muscle to
submaximal nerve stimulation but not to tetanic stimula-
tion [3, 4]; muscle force increased within the operating
range of motor unit discharge rates associated with the
voluntary activation of skeletal muscle. Increases in skel-
etal muscle strength and endurance have been observed
after single doses of tirasemtiv in patients with amyotro-
phic lateral sclerosis (ALS) and patients with peripheral
vascular disease and claudication [5, 6]. Pertinent to the
current study, tirasemtiv decreased muscle fatigability, in-
creased muscle force, and increased grip strength in a
passive transfer rat model of MG [3].
The primary objective of this early-stage clinical study was
to demonstrate an effect of single doses of tirasemtiv on mea-
sures of skeletal muscle function and fatigability in patients
with generalized MG and persistent muscle weakness. Ac-
cordingly, in this hypothesis-generating phase 2 study, multi-
ple assessments of skeletal muscle function and fatigability
were made. The secondary objectives of the study were to
evaluate and characterize the relationship, if any, between
the doses and plasma concentrations of tirasemtiv and its phar-
macodynamic effects; and to evaluate the safety and tolerabil-
ity of tirasemtiv administered as single doses to patients with
MG.
Methods
This phase 2, double-blind, placebo-controlled, random-
ized study examined 2 single doses of tirasemtiv,
250 mg and 500 mg, and placebo in a 3-way crossover
fashion. The study also measured the pharmacodynamic
properties of tirasemtiv in patients with generalized MG
on standard therapy. The study was conducted between 29
December 2010 (first patient screened) and 10 October
2012 (last patient visit completed) at 15 study centers in
the USA. Independent ethics committees at each study
site approved the protocol, and all patients provided writ-
ten informed consent before the initiation of study-
specific procedures. The study was conducted in compli-
ance with the Declaration of Helsinki and registered under
ClinicalTrials.gov identifier NCT01268280.
Study Design
Patients were randomly assigned to 1 of 6 different treatment
sequences. Each treatment sequence consisted of 3 dosing
periods in which patients received single oral doses of
250 mg or 500 mg tirasemtiv or placebo, with a washout
period of at least 7 days (up to a maximum of 10 days) be-
tween the individual doses. Treatment sequences for the 3
dosing periods were assigned as follows: sequence 1—place-
bo–tirasemtiv 250 mg–tirasemtiv 500 mg; sequence 2—pla-
cebo– tirasemtiv 500 mg–tirasemtiv 250 mg; sequence 3—
tirasemtiv 250 mg–placebo–tirasemtiv 500 mg; sequence
4—tirasemtiv 250 mg–tirasemtiv 500 mg–placebo; sequence
5—tirasemtiv 500 mg–placebo–tirasemtiv 250 mg; and se-
quence 6—tirasemtiv 500 mg–tirasemtiv 250 mg–placebo.
The single doses of tirasemtiv selected for this study
(250 mg and 500 mg) were expected to produce mean plasma
concentrations that increased the response of muscle to neu-
romuscular input, and were well tolerated by healthy male
volunteers in a previous study [4].
Only specifically designated study site pharmacy staff
were unblinded to treatment; the investigator, patient, and
remaining study site clinical staff were blinded as to treat-
ment assignment. An interactive web response system
provided patient randomization assignment to the un-
blinded pharmacists who dispensed the study medications.
All patients received 4 capsules during each dosing peri-
od. Depending on the assigned treatment sequence, each
patient received either 4 capsules of tirasemtiv (125 mg
each), 2 capsules containing tirasemtiv and 2 matching
placebo capsules, or 4 matching capsules all containing
placebo. All doses were preceded by an overnight fast
(i.e., at least 8 h) from food (not including water) and
followed by a fast from food (not including water) for
1 h postdose.
Patients
Eligible patients were aged 18–80 years, had a body mass
index between 18.0 and 36.0 kg/m2, and had an
established diagnosis of MG. The diagnosis of MG was
defined as clinical evidence of muscle weakness that could
not be better explained by another disease and a history of
an elevated acetylcholine receptor-binding antibody
titer. Patients were Myasthenia Gravis Foundation of
America clinical classification II or III, and had to have
stable weakness and treatment for 4 weeks prior to ran-
domization. Patients had to be able to perform all elements
of the Quantitative Myasthenia Gravis (QMG) assessment
[7], with QMG scores of 2 or 3 in ≥2 of the following
muscle groups: right or left arm outstretched, head lift,
and right or left leg lift at 45o. Patients could not have
received cholinesterase inhibitors for 12 h before each
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dose. Key exclusion criteria included history of any chron-
ic degenerative, psychiatric, or neurologic disorder other
than MG that produced weakness or fatigue; other major
chronic or debilitating illnesses in the 6 months prior to
study entry; renal insufficiency (serum creatinine >2.5 mg/
dl or receiving dialysis); other myasthenic syndromes; re-
ceipt of intravenous immunoglobulin, plasmapheresis
treatment, or changes to immunosuppressive treatments
in the 6 weeks prior to the first dose of study drug; receipt
of rituximab in the 3 months prior to study entry, receipt of
any investigational drug or device in the 30 days prior to
first dose of study drug; or any prior treatment with
tirasemtiv.
Outcome Measures
Safety assessments included physical examinations, elec-
trocardiograms, vital signs, and clinical laboratory evalu-
ations performed at screening and at specified times dur-
ing the study. All adverse events, whether volunteered,
elicited, or noted on physical examination or through lab-
oratory evaluations, were recorded. Pharmacodynamic as-
sessments included the following: QMG score [7], MG
Composite (MGC) score [8], the percent predicted forced
vital capacity (FVC), and manual muscle testing (MG-
MMT) of selected muscles [9]. The QMG score is a 39-
point scale that assesses diplopia (to primary and lateral
gaze) right or left, ptosis, facial muscles, swallowing, dys-
arthria with counting, right and left arm held outstretched
at 90o, FVC (percent predicted), right and left hand grip,
head lift 45o supine, and right and left leg held
outstretched at 45o supine [7]. Each assessment is graded
from 0 to 3 points, with 3 points representing the most
severe dysfunction; thus, lower scores represent better
function. The MGC is a validated, 10-item assessment
based on physician examination and patient history, in
which a 3-point improvement on a total scale of 0–50
indicates clinical improvement [8]. The MG-MMT as-
sesses neck flexion and extension, shoulder abduction
(deltoid), and hip flexion [9]. Pharmacodynamic outcomes
were assessed at screening (QMG only) and at 0, 3, 6, and
24 h (QMG, FVC, MGC, MG-MMT) after dosing.
Statistical Considerations
A sample size of 6 patients per treatment sequence (total
of 36 patients) was estimated to provide 90 % power to
detect a difference in mean QMG score of 0.60 SDs with
a 2-sided significance level of 0.05. Descriptive statistics
are presented for continuous (n, mean, median, SD,
range) and categorical (number and percentage of pa-
tients) variables. Adverse events were categorized using
the Medical Dictionary for Regulatory Activity version
10.1. Statistical analyses were performed using SAS for
Windows, Version 9.2 (SAS Institute, Cary, NC, USA).
Change from predose baseline in QMG total score,
MGC total score, and FVC were analyzed by time using
repeated measures analysis of covariance analyses with
treatment, sequence, and period as fixed effects, the cor-
responding predose baseline value from each period as the
covariate, and patient as a random effect in the model.
Table 1 Demographics and clinical characteristics at baseline
All patients (n=32)
Mean age, years (SD) 54.4 (19.8)




Black/African American 3 (9.4)
Other 6 (18.8)
BMI, mean kg/m2 (SD) 29.2 (4.7)
QMG total score, mean (SD) 16.6 (4.9)
MGC score, mean (SD) 11.0 (6.6)
FVC, mean l/min (SD) 2.98 (0.89)
FVC % predicted, mean (SD) 77.4 (16.2)
MG-MMT total score, mean (SD) 6.3 (4.5)
BMI = body mass index; QMG = Quantitative Myasthenia Gravis; MGC
= Myasthenia Gravis Composite; FVC = forced vital capacity; MMT =
manual muscle tests
Table 2 Quantitative myasthenia gravis (QMG) total score change (pharmacodynamic population)
Placebo (n=32) Tirasemtiv 250 mg (n=32) Tirasemtiv 500 mg (n=32)
Baseline QMG, mean total score (SD) 15.8 (5.3) 15.5 (5.1) 15.8 (5.0)
QMG change from baseline to hour 3, differences in
LSM from placebo (95 % CI)
NA 0.1 (–1.0 to 1.3) –0.2 (–1.3 to 0.9)
QMG change from baseline to hour 6, differences in
LSM from placebo (95 % CI)
NA –0.3 (–1.1 to 0.5) –1.0 (–1.8 to –0.2)*
LSM = least square means; CI = confidence interval; NA = not applicable
*p<0.05
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Treatment effect over both 3 and 6 h postdose was ana-
lyzed by including a time point variable in the model
statement. For FVC, with 3 trials performed at each time
point, the changes from predose baseline were analyzed
by time using repeated measures analysis of covariance
analyses with treatment, sequence, trial, and period as
fixed effects, the corresponding baseline value as a covar-
iate, and patient as a random effect in the model. p-Values
and 95 % confidence intervals were calculated for treat-
ment differences at each time point between active dose
levels and placebo. No primary efficacy variable was
prespecified and no adjustments were made for multiple
comparisons.
The safety population (all patients who received any
amount of study drug) was used for the evaluation of
patient disposition, demographics, clinical characteristics,
and all safety outcomes. The pharmacodynamic popula-
tion (all patients in the safety population who had at least
1 postbaseline pharmacodynamic assessment and no ma-




A total of 32 patients (of 36 planned) were enrolled in the
study and randomly assigned to 1 of 6 treatment sequences
of tirasemtiv (250mg and 500mg) and placebo. Themean age
of the patients was 54.4 years; half were male; and the study
population was predominantly white (66 %) (Table 1). All
patients were included in the safety population, and all pa-
tients were eligible to be included in the pharmacodynamics
population.
Pharmacodynamic Outcomes
No statistically significant differences in QMG total score
between placebo and either tirasemtiv dose were noted at
3 h after dosing (Table 2). At 6 h after dosing, dose-
related improvement from baseline (i.e., decreases) in
the QMG total score were found with an increase of














































































A  QMG Change From Baseline B  Patients with    3-point QMG Change
*
†
Fig. 1 Quantitative Myasthenia
Gravis (QMG) total scores and
patients with change in QMG
total score ≥3 points at 6 h after
dosing. The (A) least square mean
change in QMG total score by
treatment and (B) number of
patients who achieved a ≥3-point
change in QMG total score
(indicating clinical improvement)
are shown. Error bars represent
SE. *p=0.02 vs placebo; †p=0.098
vs placebo based on χ2 test
Table 3 Forced vital capacity (FVC) and percent predicted FVC (pharmacodynamic population)




Baseline FVC, mean l/min (SD) 3.0 (0.8) 3.0 (0.9) 3.1 (0.9)
FVC change from baseline to hour 3, differences in LSM from placebo (95 % CI) 0.04 (–0.02 to 0.10) 0.03 (–0.03 to 0.09)
FVC change from baseline to hour 6, differences in LSM from placebo (95 % CI) 0.17 (0.05, 0.29)* 0.06 (–0.07 to 0.18)
Baseline percent predicted FVC, mean % (SD) 80.9 (20.5) 81.5 (17.8) 81.8 (20.2)
Percent predicted FVC change from baseline to hour 3,
differences in LSM from placebo (95 % CI)
–0.31 (–2.51 to 1.88) –1.95 (–4.14 to 0.24)
Percent predicted FVC change from baseline to hour 6,
differences in LSM from placebo (95 % CI)
6.98 (2.79–11.17)* 4.53 (0.34–8.73)†
LSM = least square means; CI = confidence interval
*p<0.01; † p<0.05
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FVC (slope: 2.2 % per 250 mg; p=0.04). The least squares mean
differences (SE) between treatment and placebo were –0.3 (0.4)
for tirasemtiv 250 mg (p=0.48) and –1.0 (0.4) for tirasemtiv
500 mg (p=0.02), as shown in Fig. 1A. In a responder analysis,
twice as many patients receiving tirasemtiv 500 mg improved by
≥3 points in their QMG total score compared with those receiving
placebo (p=0.098) (Fig. 1B).
FVC (percent predicted) at either dose of tirasemtiv was
not significantly different from placebo at 3 h, and no statisti-
cally significant dose trend was observed (Table 3). At 6 h,
however, compared with placebo, the least square mean (SE)
change from baseline in percent predicted FVC was 7.0 %
(2.1 %) for tirasemtiv 250 mg (p<0.01) and 4.5 % (2.1 %)
for tirasemtiv 500 mg (p=0.03).
Overall, tirasemtiv did not show evidence of a posi-
tive effect on the MGC and MG-MMT scores (data not
shown).
Safety
No patients experienced a serious adverse event during
the study, and no patients discontinued from the study
because of an adverse event. Overall, 25 (78.1 %) patients
had at least 1 treatment-emergent adverse event (Table 4).
The most commonly reported treatment-emergent adverse
events were dizziness (46.9 % on tirasemtiv and 6.3 % on
placebo) and headache (12.5 % on tirasemtiv and 9.4 %
on placebo). The duration of dizziness episodes ranged
from 0.3 to 73.0 h. Most adverse events were mild or
moderate in severity; 1 patient reported flushing as an
adverse event of severe intensity with tirasemtiv 500 mg.
Discussion
The results from this study suggest that tirasemtiv was
well tolerated and may improve function in patients with
MG. Dose-related improvements in QMG were observed
with tirasemtiv, and twice as many patients had clinically
significant improvements in QMG (>3 points) at 6 h after
the 500 mg dose compared with placebo. Adverse events
reported in this study were consistent with those observed
in previous studies conducted in healthy volunteers [4],
patients with ALS [5], and patients with calf claudication
[6], most notably dizziness (which was dose-dependent),
ataxia, and nausea. Adverse events were mostly mild in
severity.
Patients did not receive their usual dose of pyridostigmine
prior to the baseline assessment in order to ensure that there
was some dysfunction at baseline. It is possible that the
modest treatment effects observed actually underestimate
the potential effect of tirasemtiv if it were to be given with
pyridostigmine, as their mechanisms should be comple-
mentary; the possibility that clinical benefit would be
greater in patients taking pyridostigmine warrants further
evaluation.
A limitation of this study was the small sample size,
which was not sufficient to prove clinical efficacy. As no
primary efficacy end point was prespecified, there was no
adjustment of p-values for multiple comparisons; thus, our
findings should be considered as hypothesis-generating.
Additionally, the short duration of the study does not pro-
vide information on long-term effects of treatment with
tirasemtiv, which will be important for chronic diseases
such as ALS and MG. Patients with more severe disease,
such as Myasthenia Gravis Foundation of America grade
IV, and patients without acetylcholine receptor-
binding antibodies were excluded from the study, and
the results may not be generalizable to patients with those
disease characteristics. Tirasemtiv provides only function-
al improvement, and is not likely to reverse the immuno-
logic processes that drive the pathogenesis of MG or pre-
vent disease progression.
In conclusion, this study indicated that tirasemtiv
may improve muscle weakness and fatigue associated
with MG. The results from this study support further
development of tirasemtiv to investigate its potential as
a treatment for MG.












13 (40.6) 12 (37.5) 21 (65.6)
Patients with a severe
adverse event
0 0 1 (3.1)
Adverse events occurring in ≥2 patients
Dizziness 2 (6.3) 7 (21.9) 13 (40.6)
Headache 3 (9.4) 2 (6.3) 2 (6.3)
Dyspnea 0 1 (3.1) 2 (6.3)
Pollakiuria 1 (3.1) 0 3 (9.4)
Balance disorder 0 0 3 (9.4)
Feeling drunk 0 2 (6.3) 1 (3.1)
Anxiety 0 1 (3.1) 1 (3.1)
Blurred vision 0 1 (3.1) 2 (6.3)
Diarrhea 2 (6.3) 0 2 (6.3)
Dry mouth 1 (3.1) 0 1 (3.1)
Vomiting 1 (3.1) 0 1 (3.1)
Urinary tract
infection
0 1 (3.1) 1 (3.1)
Muscle spasm 0 1 (3.1) 2 (6.3)
Values are given as n (%)
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